Ghrelin Peptide Research: GHSR-1a Signaling, Acylation Mechanism, and Preclinical Evidence

Ghrelin is a 28-residue peptide hormone from the stomach, n-octanoylated on serine 3, that is the endogenous ligand of the growth hormone secretagogue receptor GHSR-1a, and ghrelin peptide research covers growth hormone release, hypothalamic control of feeding and adiposity, islet insulin secretion, cardiac remodelling and hippocampal and nigral neuroprotection. It is the only known hormone whose activity depends on an octanoyl ester, the modification is added by ghrelin O-acyltransferase (GOAT), and that ester is also the reason ghrelin is one of the hardest peptides to measure and to keep intact in a research setting. This article summarises the primary literature and corrects a number of figures that circulated in the earlier version of this page. Ghrelin itself is a reference compound discussed for its pharmacology; it is not an item in the Maple Research Labs catalogue.

Disclaimer: For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information presented here is drawn from published scientific literature and is intended solely for educational reference.

Discovery and Molecular Structure

Ghrelin was discovered by reverse pharmacology. The receptor GHS-R had been cloned as the target of synthetic growth hormone secretagogues, which implied that an endogenous ligand existed and that a GH-releasing mechanism distinct from hypothalamic GHRH must operate. Kojima and colleagues purified that ligand from rat stomach and found a 28-residue peptide in which serine 3 carries an n-octanoyl group; the acylated peptide released GH in vivo and in vitro, the octanoylation was essential for activity, and human ghrelin differed from rat ghrelin at two positions (Kojima et al., 1999, Nature 402:656-660; PMID 10604470). The two species differ at residues 11 and 12 (Arg-Val in human, Lys-Ala in rat), which gives acylated human ghrelin a molecular weight of about 3371 Da and rat ghrelin about 3315 Da. The earlier version of this page gave 3314.9 Da as the mass of “the 28-mer” without saying it is the rat peptide; a certificate of analysis for human ghrelin should show the higher mass.

The acylating enzyme was identified in 2008. GOAT is a polytopic membrane-bound enzyme belonging to a family of sixteen hydrophobic acyltransferases that includes Porcupine, which lipidates Wnt proteins; it is the only family member that octanoylates ghrelin when co-expressed with preproghrelin in endocrine cell lines, its activity requires conserved catalytic asparagine and histidine residues, and its mRNA is largely restricted to stomach and intestine (Yang et al., 2008, Cell 132:387-396; PMID 18267071). Des-acyl ghrelin, which lacks the octanoyl group, is the major form in circulation and does not activate GHSR-1a, although it is not biologically inert; the percentage figures for the des-acyl fraction quoted in the earlier version of this page had no source and have been removed.

GHSR-1a Signalling and Constitutive Activity

GHSR-1a is a Gq/11-coupled receptor: agonist binding activates phospholipase C-beta, raises inositol phosphates and intracellular calcium, and drives GH exocytosis from somatotrophs. That the receptor is the physiological ghrelin receptor was shown genetically by Sun and colleagues, who found that acute ghrelin stimulated neither GH release nor food intake in Ghsr-null mice, while the null mice were not dwarfs and had appetite and body composition comparable to wild-type littermates (Sun et al., 2004, PNAS 101:4679-4684; PMID 15070777). The “approximately 50 percent lower GH amplitude in GHSR knockouts” figure previously on this page is not what that paper reports.

The receptor’s most unusual property is its ligand-independent signalling. Holst and colleagues showed that in transfected COS-7 and HEK293 cells the ghrelin receptor signals strongly through inositol phosphate turnover and CRE-driven transcription with no ligand present, that ghrelin and the non-peptide secretagogues stimulate turnover further, and that the low-potency antagonist [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P is in fact a full inverse agonist with an EC50 of 5.2 nM that brings signalling down to the level of untransfected cells; the motilin receptor, used as a control, showed no constitutive activity at all (Holst et al., 2003, Mol Endocrinol 17:2201-2210; PMID 12907757). Constitutive activity of this magnitude is why apparent “antagonist” data at GHSR-1a need to be read carefully: a compound can lower signalling below baseline without competing with ghrelin at all. The “Korbonits 2003 Endocrine Reviews, 40 percent calcium, n=18” citation on the earlier page could not be located and has been removed.

Feeding, Adiposity and the Hypothalamic Circuit

Tschöp, Smiley and Heiman showed that daily peripheral ghrelin caused weight gain in mice and rats by reducing fat utilisation, that intracerebroventricular ghrelin produced a dose-dependent increase in food intake and body weight, and that rat serum ghrelin rose with fasting and fell with re-feeding or oral glucose but not with water (Tschöp et al., 2000, Nature 407:908-913; PMID 11057670). The specific 30 to 80 percent intake increase, the nmol/kg range and the n of 24 attached to this study in the earlier version of this page are not in the abstract. Nakazato and colleagues then placed the effect in the hypothalamus: intracerebroventricular ghrelin strongly stimulated feeding in rats, including GH-deficient rats, anti-ghrelin IgG suppressed feeding, ghrelin induced Fos in NPY and AgRP neurons, antibodies and antagonists of NPY and AgRP abolished ghrelin-induced feeding, and ghrelin raised NPY expression and blocked the anorectic effect of leptin (Nakazato et al., 2001, Nature 409:194-198; PMID 11196643).

Cowley and colleagues mapped the circuit electrophysiologically. They found ghrelin-expressing neurons adjacent to the third ventricle sending efferents onto NPY, AgRP, POMC and CRH neurons, ghrelin binding mostly on presynaptic terminals of NPY neurons, and ghrelin stimulating arcuate NPY neurons while mimicking the effect of NPY in the paraventricular nucleus (Cowley et al., 2003, Neuron 37:649-661; PMID 12597862). The “3.5-fold increase in NPY/AgRP firing” figure previously quoted is not in that paper. Our neuropeptide Y summary covers the downstream arm of this circuit, and LEAP-2, the endogenous GHSR-1a antagonist, is the natural counterweight to ghrelin at the receptor.

Adipogenesis and Islet Insulin Secretion

Choi and colleagues found that GHS-R mRNA in rat epididymal and parametrial fat rose up to four-fold between 4 and 20 weeks of age and increased during preadipocyte differentiation, that ghrelin at 10 nM for 10 days stimulated glycerol-3-phosphate dehydrogenase activity and differentiation of rat preadipocytes, that ghrelin raised PPAR-gamma 2 mRNA in differentiated adipocytes, and that ghrelin dose-dependently reduced isoproterenol-stimulated lipolysis (Choi et al., 2003, Endocrinology 144:754-759; PMID 12586750). The paper is from 2003, not 2004, and reports no 35 percent triglyceride figure.

In the islet, Dezaki and colleagues detected acylated ghrelin in rodent pancreatic islets and showed that blocking endogenous ghrelin with GHS-R antagonists lowered fasting glucose, attenuated the glucose excursion and enhanced the insulin response during a glucose tolerance test, whereas exogenous ghrelin did the opposite in a GH-independent manner, with no effect of either on insulin tolerance; the mechanism is attenuation of glucose-induced calcium signalling in beta cells (Dezaki et al., 2004, Diabetes 53:3142-3151; PMID 15561944). The “20 to 30 percent suppression of glucose-stimulated insulin secretion” figure previously attached to this finding is not in the abstract. The GOAT inhibitor GO-CoA-Tat, a peptide-based bisubstrate analogue, inhibits GOAT in vitro, in cells and in mice, and improved glucose tolerance and reduced weight gain in wild-type but not ghrelin-deficient mice, confirming that the metabolic effects run through ghrelin acylation (Barnett et al., 2010, Science 330:1689-1692; PMID 21097901). The “greater than 80 percent reduction in acylated ghrelin” figure could not be verified and has been removed, as has the unverifiable “Xu 2012 Metabolism” mitochondrial complex activity study.

Cardiovascular Research

The cardiac literature is more specific than the earlier version of this page implied. Soeki and colleagues gave ghrelin subcutaneously twice daily for two weeks to Sprague-Dawley rats from the day after coronary ligation (n=15 per group). Left ventricular enlargement was significantly attenuated compared with saline, LV end-diastolic pressure fell and the peak rates of pressure rise and fall improved, and telemetric power spectral analysis in conscious infarcted rats showed that ghrelin suppressed cardiac sympathetic activity, which the authors propose as the mechanism of the anti-remodelling effect (Soeki et al., 2008, Am J Physiol Heart Circ Physiol 294:H426-H432; PMID 18024547). That paper is in the American Journal of Physiology, not the Journal of Cardiovascular Pharmacology, and reports no infarct-size or ejection-fraction percentages of the kind previously quoted. In human chronic heart failure, plasma ghrelin was significantly higher in cachectic than in non-cachectic patients, alongside higher GH, TNF-alpha, noradrenaline and angiotensin II, which the authors read as a compensatory anabolic response (Nagaya et al., 2001, Circulation 104:2034-2038; PMID 11673342). The “Mao 2009 European Journal of Pharmacology” infarct study and the des-acyl ghrelin caspase-3 figure could not be located and have been removed.

Neurological Research

Circulating ghrelin enters the hippocampus and binds hippocampal neurons, where it promotes dendritic spine synapse formation and the generation of long-term potentiation, with parallel improvements in spatial learning and memory; ghrelin-knockout mice have fewer CA1 spine synapses and impaired memory performance, both rapidly reversed by ghrelin administration (Diano et al., 2006, Nat Neurosci 9:381-388; PMID 16491079). The paper is from 2006, not 2011, its model is the ghrelin knockout rather than food restriction, and it reports no 30 percent spine density figure.

In the nigrostriatal system, Andrews and colleagues showed that the substantia nigra pars compacta expresses GHSR, that ghrelin binds and electrically activates nigral dopamine neurons, raises tyrosine hydroxylase mRNA and increases striatal dopamine, that exogenous ghrelin decreased nigral dopamine cell loss and striatal dopamine loss after MPTP, and that genetic ablation of ghrelin or GHSR increased MPTP-induced loss in a manner reversed by re-expressing GHSR in catecholaminergic neurons, with the protection depending on mitochondrial UCP2 (Andrews et al., 2009, J Neurosci 29:14057-14065; PMID 19906954). The model is MPTP in mice, not 6-OHDA in rats, and the “45 percent” figure and the alpha-synuclein autophagy mechanism previously stated are not in the paper.

Key Research Findings

Ghrelin is a 28-residue stomach peptide whose serine 3 octanoylation, added by GOAT, is essential for GHSR-1a activity, and human and rat ghrelin differ at two residues (Kojima 1999; Yang 2008). GHSR-1a mediates ghrelin’s effects on GH release and food intake, since Ghsr-null mice respond to neither, yet the null mice grow normally (Sun 2004). The receptor is highly constitutively active, and a substance P analogue is a full inverse agonist (Holst 2003). Peripheral ghrelin induces adiposity by reducing fat utilisation, central ghrelin increases feeding dose-dependently, and the feeding effect runs through NPY and AgRP neurons and is abolished by their antagonists (Tschöp 2000; Nakazato 2001; Cowley 2003). Ghrelin promotes rat preadipocyte differentiation and PPAR-gamma 2 expression and reduces lipolysis (Choi 2003), and endogenous islet ghrelin restricts insulin release through beta-cell calcium signalling, so GHS-R antagonism lowers fasting glucose (Dezaki 2004); a GOAT inhibitor reproduces this metabolic benefit only in ghrelin-competent mice (Barnett 2010). Two weeks of ghrelin after myocardial infarction attenuates LV remodelling and suppresses cardiac sympathetic activity in rats (Soeki 2008). Ghrelin drives hippocampal spine synapse formation and LTP (Diano 2006) and protects nigral dopamine neurons against MPTP through UCP2 (Andrews 2009).

Ghrelin Analogues and GHSR-1a Research Tools

The synthetic secretagogues that predated ghrelin, GHRP-2, GHRP-6, hexarelin and ipamorelin, are all GHSR-1a agonists, and their binding, selectivity and GH-pulse data can only be interpreted against the receptor pharmacology above, including its constitutive activity. Ipamorelin’s absence of ACTH and cortisol release at doses far above its GH ED50 is the property that distinguishes it from GHRP-6, as set out in our ipamorelin GHSR-1a selectivity and GHRP-6 pharmacology summaries. GOAT inhibitors such as GO-CoA-Tat reduce endogenous acyl ghrelin without touching the receptor and are the cleanest tool for separating ligand-dependent from constitutive GHSR-1a signalling.

Measurement and Research Methodology

The octanoyl ester at serine 3 is chemically labile. Hosoda and colleagues showed that it is rapidly hydrolysed to des-acyl ghrelin in blood samples and defined the collection and storage conditions needed to preserve it, which is why acylated ghrelin measurements require immediate cooling, protease inhibition, acidification and freezing rather than standard serum handling (Hosoda et al., 2004, Clin Chem 50:1077-1080; PMID 15161728). Immunoassays specific for the acylated N-terminus report acyl ghrelin, total assays report both forms, and LC-MS/MS now quantifies the two together, as discussed in our mass spectrometry article.

The same chemistry governs a research lot. Acyl ghrelin can lose its octanoyl group during aqueous handling and storage, and a de-acylated preparation will show essentially no GHSR-1a activity while still looking like a clean single peak by HPLC. A certificate of analysis for ghrelin therefore needs a mass spectrometry identity result that confirms the acylated mass, 3371 Da for human or 3315 Da for rat, and not merely a purity percentage, and solutions should be kept acidic, cold and in single-use aliquots per the storage guide. How to read those results against the lot on the vial is covered in our COA guide.

Note on sources. This article was rewritten in September 2026 after a citation audit. The earlier version attributed the discovery to a “2001 Trends in Endocrinology and Metabolism” paper rather than Kojima 1999 in Nature, gave the rat ghrelin mass as if it were the human peptide, cited “Korbonits 2003 Endocrine Reviews”, “Xu 2012 Metabolism” and “Mao 2009 European Journal of Pharmacology” studies that could not be located, misplaced Soeki 2008 in the Journal of Cardiovascular Pharmacology with invented infarct and ejection-fraction figures, misdated Diano 2006 to 2011 and Choi 2003 to 2004, described Andrews 2009 as a 6-OHDA rat study when it is an MPTP mouse study, and attached percentages, doses, sample sizes and EC50 values to Tschöp 2000, Cowley 2003, Dezaki 2004, Sun 2004 and Barnett 2010 that do not appear in those papers. Every citation above was checked against the indexed abstract on 18 September 2026.

Ghrelin and the urocortins pull in opposite directions on feeding circuits in rodent models, and both have cardiovascular literatures of their own; our urocortin summary covers the stress-axis side of that comparison. Maple Research Labs submits manufactured batches of its catalogue compounds to an independent analytical laboratory for HPLC testing and publishes the per-batch result on the certificates of analysis page; ghrelin is not a catalogue compound, and the GHSR-1a agonists currently listed can be found in the research peptide catalogue.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.